Smoking Cessation Clinical Trial
Official title:
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Verified date | April 2010 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
Status | Completed |
Enrollment | 504 |
Est. completion date | April 2009 |
Est. primary completion date | July 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 35 Years and older |
Eligibility |
Inclusion Criteria: - Subjects will be current cigarette smokers who have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit. - mild to moderate COPD confirmed by spirometry - Subjects must have a clinical diagnosis of COPD. Exclusion Criteria: - Subjects who have made a serious attempt to quit smoking in the past 3 months. - Subjects who have been previously randomized in a study that has included varenicline. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Pfizer Investigational Site | Brest | |
France | Pfizer Investigational Site | Montpellier Cedex 5 | |
France | Pfizer Investigational Site | Nice | |
France | Pfizer Investigational Site | Paris cedex 14 | |
Italy | Pfizer Investigational Site | Modena | |
Italy | Pfizer Investigational Site | Pisa | |
Italy | Pfizer Investigational Site | Vittorio Veneto, TV | |
Spain | Pfizer Investigational Site | Caceres | |
Spain | Pfizer Investigational Site | L'hospitalet Del Llobregat | Barcelona |
Spain | Pfizer Investigational Site | Madrid | |
United States | Pfizer Investigational Site | Birmingham | Alabama |
United States | Pfizer Investigational Site | Chapel Hill | North Carolina |
United States | Pfizer Investigational Site | Chapel Hill | North Carolina |
United States | Pfizer Investigational Site | Denver | Colorado |
United States | Pfizer Investigational Site | Farmington | Connecticut |
United States | Pfizer Investigational Site | Farmington | Connecticut |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Lexington | Kentucky |
United States | Pfizer Investigational Site | Los Angeles | California |
United States | Pfizer Investigational Site | Los Angeles | California |
United States | Pfizer Investigational Site | Miami | Florida |
United States | Pfizer Investigational Site | Nashville | Tennessee |
United States | Pfizer Investigational Site | North Dartmouth | Massachusetts |
United States | Pfizer Investigational Site | Omaha | Nebraska |
United States | Pfizer Investigational Site | Philadelphia | Pennsylvania |
United States | Pfizer Investigational Site | Portland | Oregon |
United States | Pfizer Investigational Site | Portland | Maine |
United States | Pfizer Investigational Site | Raleigh | North Carolina |
United States | Pfizer Investigational Site | Rochester | New York |
United States | Pfizer Investigational Site | Rochester | Minnesota |
United States | Pfizer Investigational Site | Winston-Salem | North Carolina |
United States | Pfizer Investigational Site | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, France, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects With Four Week Continuous Quit Rate (CQR) | Number of subjects who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory [NUI]) and with end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm) for weeks 9 through 12 (inclusive). | Week 9 through Week 12 | No |
Secondary | Number of Subjects With Continuous Abstinence (CA) | Number of subjects who reported no smoking and no use of other nicotine-containing products (treatment phase = through week 12) or tobacco products (non-treatment phase = after treatment phase; follow up through week 52) at each contact (on the NUI) and with end-expiratory exhaled CO measurement less than or equal to 10 ppm from week 9 through week 24 and week 52. CO confirmed in-clinic visit. | Week 9 through Week 24 and Week 52 | No |
Secondary | Number of Subjects With Long Term Quit Rate (LTQR) | Number of subjects who were responders for the primary endpoint (4-week CQR for Weeks 9 through 12) and who had no more than 6 cumulative days of smoking from Week 12 through the given visit (Week 24 and Week 52). CO confirmed in-clinic visit. |
Week 24, Week 52 | No |
Secondary | Number of Subjects With 7-Day Point Prevalence of Abstinence | Number of subjects at given visit (Week 12, Week 24, Week 52) or telephone contact, reported no smoking and no use of other nicotine-containing products (treatment phase) or tobacco products (non-treatment phase) in the last 7 days and with end-expiratory exhaled CO measurement less than or equal to 10 ppm. CO confirmed in-clinic visit. | Week 12, Week 24, Week 52 | No |
Secondary | Number of Subjects With 4-Week Point Prevalence of Abstinence | Number of subjects at Week 52 visit reporting no smoking and no use of other tobacco products in the last 4 weeks and with end-expiratory exhaled CO measurement less than or equal to 10 ppm. | Week 52 | No |
Secondary | Change From Baseline in Pre-bronchodilator and Post-bronchodilator Forced Expiratory Volume in First Second (FEV1) | Change from baseline in mean FEV1 (forced expiratory volume in the first second of forced exhalation) measured in millimeters (ml) as mean at observation minus baseline value. Directly after pre-bronchodilator measurement, subject inhaled albuterol or salbutamol delivered by metered-dose inhaler (MDI); post-bronchodilator lung function repeated 30 to 45 minutes following administration of albuterol or salbutamol. | Baseline, Week 12, Week 52 | No |
Secondary | Change From Baseline in Clinical COPD Questionnaire (CCQ) | Change from baseline: mean at observation minus baseline value. Subject-administered 10-item instrument to systematically assess COPD symptoms (items 1, 2, 5, and 6), functional states (items 7, 8, 9, and 10) and mental states (items 3 and 4); For each domain score = sum of items divided by the number of items; total score = sum of scores divided by 10; range from 0 (very good health) to 6 (extremely poor health). Assessed at each visit based on subject's experience during the week prior to visit. | Baseline, Week, 12, Week 24, Week 52 | No |
Secondary | Number of Cigarettes Smoked Daily During First 3 Weeks of the 12-Week Treatment Period | Number of cigarettes smoked daily collected during the first 3 weeks of study after randomization using patient smoking diaries. | Day 1 through Day 21 | No |
Secondary | Change From Baseline in Inflammatory Biomarkers: C-Reactive Protein (CRP) and Fibrinogen Antigen | Change from baseline in CRP and Fibrinogen antigen (blood markers of inflammation) calculated as mean at observation minus baseline value; measured as milligrams per deciliter (mg/dl). | Baseline, Week 12, Week 52 | No |
Secondary | Change From Baseline in Body Weight | Change from baseline calculated as mean at observation minus baseline value; body weight measured in kilograms (kg). | Baseline, Week 52 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT04617444 -
The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function
|
N/A | |
Completed |
NCT02796391 -
Facilitating Smoking Cessation With Reduced Nicotine Cigarettes
|
Phase 2 | |
Completed |
NCT03397511 -
Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City
|
N/A | |
Not yet recruiting |
NCT05188287 -
A Culturally Tailored Smartphone Application for African American Smokers
|
N/A | |
Recruiting |
NCT05264428 -
The Effect of Honey on Lessening the Withdrawal Symptoms
|
N/A | |
Recruiting |
NCT05846841 -
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
|
N/A | |
Completed |
NCT04133064 -
Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study
|
N/A | |
Completed |
NCT03187730 -
Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants
|
Phase 4 | |
Completed |
NCT03474783 -
To Explore the Factors Affecting the Effectiveness of Smoking Cessation
|
N/A | |
Completed |
NCT04635358 -
Feasibility Study of Smoking Cessation for the Staff of a Hospital Center
|
N/A | |
Terminated |
NCT03670264 -
BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation
|
N/A | |
Not yet recruiting |
NCT06307496 -
VIDeOS for Smoking Cessation
|
N/A | |
Completed |
NCT02997657 -
Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT02905656 -
Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit
|
N/A | |
Completed |
NCT03206619 -
A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
|
||
Completed |
NCT02239770 -
Pharmacokinetics of Nicotine Film in Smokers
|
N/A | |
Completed |
NCT02562521 -
A Smoking Cessation Intervention for Yale Dining Employees
|
Phase 4 | |
Recruiting |
NCT02422914 -
Benefits of Tobacco Free Cigarette
|
N/A |